BEAM (carmustine [bis-chloroethylnitrosourea (BCNU)]-etoposide-cytarabine-melphalan) chemotherapy is the standard conditioning regimen for autologous stem cell transplantation (ASCT) in lymphomas. Owing to BCNU shortages, many centers switched to fotemustine-substituted BEAM (FEAM), lacking proof of equivalence. We conducted a retrospective cohort study in 18 Italian centers to compare the safety and efficacy of BEAM and FEAM regimens for ASCT in lymphomas performed from 2008 to 2015. We enrolled 1038 patients (BEAM = 607, FEAM = 431), of which 27% had Hodgkin lymphoma (HL), 14% indolent non-Hodgkin lymphoma (NHL), and 59% aggressive NHL. Baseline characteristics including age, sex, stage, B-symptoms, extranodal involvement, previous treatments, response before ASCT, and overall conditioning intensity were well balanced between BEAM and FEAM; notable exceptions were median ASCT year (BEAM = 2011 versus FEAM = 2013, P <.001), Sorror score ≥3 (BEAM = 15% versus FEAM = 10%, P =.017), and radiotherapy use (BEAM = 18% versus FEAM = 10%, P <.001). FEAM conditioning resulted in higher rates of gastrointestinal and infectious toxicities, including severe oral mucositis grade ≥3 (BEAM = 31% versus FEAM = 44%, P <.001), and sepsis from Gram-negative bacteria (mean isolates/patient: BEAM =.1 versus FEAM =.19, P <.001). Response status at day 100 post-ASCT (overall response: BEAM = 91% versus FEAM = 88%, P =.42), 2-year overall survival (83.9%; 95% confidence interval [CI], 81.5% to 86.1%) and progression-free survival (70.3%; 95% CI, 67.4% to 73.1%) were not different in the two groups. Mortality from infection was higher in the FEAM group (subhazard ratio, 1.99; 95% CI, 1.02 to 3.88; P =.04). BEAM and FEAM do not appear different in terms of survival and disease control. However, due to concerns of higher toxicity, fotemustine substitution in BEAM does not seem justified, if not for easier supply.

A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi

Ferrero S.;Ghione P.;
2018

Abstract

BEAM (carmustine [bis-chloroethylnitrosourea (BCNU)]-etoposide-cytarabine-melphalan) chemotherapy is the standard conditioning regimen for autologous stem cell transplantation (ASCT) in lymphomas. Owing to BCNU shortages, many centers switched to fotemustine-substituted BEAM (FEAM), lacking proof of equivalence. We conducted a retrospective cohort study in 18 Italian centers to compare the safety and efficacy of BEAM and FEAM regimens for ASCT in lymphomas performed from 2008 to 2015. We enrolled 1038 patients (BEAM = 607, FEAM = 431), of which 27% had Hodgkin lymphoma (HL), 14% indolent non-Hodgkin lymphoma (NHL), and 59% aggressive NHL. Baseline characteristics including age, sex, stage, B-symptoms, extranodal involvement, previous treatments, response before ASCT, and overall conditioning intensity were well balanced between BEAM and FEAM; notable exceptions were median ASCT year (BEAM = 2011 versus FEAM = 2013, P <.001), Sorror score ≥3 (BEAM = 15% versus FEAM = 10%, P =.017), and radiotherapy use (BEAM = 18% versus FEAM = 10%, P <.001). FEAM conditioning resulted in higher rates of gastrointestinal and infectious toxicities, including severe oral mucositis grade ≥3 (BEAM = 31% versus FEAM = 44%, P <.001), and sepsis from Gram-negative bacteria (mean isolates/patient: BEAM =.1 versus FEAM =.19, P <.001). Response status at day 100 post-ASCT (overall response: BEAM = 91% versus FEAM = 88%, P =.42), 2-year overall survival (83.9%; 95% confidence interval [CI], 81.5% to 86.1%) and progression-free survival (70.3%; 95% CI, 67.4% to 73.1%) were not different in the two groups. Mortality from infection was higher in the FEAM group (subhazard ratio, 1.99; 95% CI, 1.02 to 3.88; P =.04). BEAM and FEAM do not appear different in terms of survival and disease control. However, due to concerns of higher toxicity, fotemustine substitution in BEAM does not seem justified, if not for easier supply.
24
9
1814
1822
Autologous; BEAM regimen; Fotemustine; Lymphoma; Transplantation; Transplantation conditioning; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Lymphoma; Male; Melphalan; Middle Aged; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous
Olivieri J.; Mosna F.; Pelosini M.; Fama A.; Rattotti S.; Giannoccaro M.; Carli G.; Tisi M.C.; Ferrero S.; Sgherza N.; Mazzone A.M.; Marino D.; Calimeri T.; Loseto G.; Saraceni F.; Tomei G.; Sica S.; Perali G.; Codeluppi K.; Billio A.; Olivieri A.; Orciuolo E.; Matera R.; Stefani P.M.; Borghero C.; Ghione P.; Cascavilla N.; Lanza F.; Chiusolo P.; Finotto S.; Federici I.; Gherlinzoni F.; Centurioni R.; Fanin R.; Zaja F.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1791409
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 12
social impact